According to the Pacific Securities Research Report, the domestic recovery trend of the new industry in 26Q2 was remarkable, and the volume and quality of overseas business rose sharply. The first half of the year achieved net profit of 868 million yuan, an increase of 12.53% over the previous year; of these, net profit to mother was 426 million yuan in the second quarter of 2026, an increase of 27.63% over the previous year. The company's domestic business showed a recovery trend in the first half of the year, thanks to the company's major customer strategy in the domestic market that continued to advance in the domestic market for the past two years after experiencing price drops after the implementation of the domestic inter-provincial alliance procurement and the DRG/DIP policy, the company's domestic business showed a recovery trend in the first half of the year. The company continues its major customer marketing strategy and continues to expand large-scale domestic medical terminals through the promotion of high-speed chemiluminescence immunoanalyzers X10, X8, X6 and assembly line product T8. With the continuous deepening of the globalization strategy, the company's overseas business achieved a sharp rise in quantity and quality. Maintain a “buy” rating.

According to the Pacific Securities Research Report, the domestic recovery trend of the new industry in 26Q2 was remarkable, and the volume and quality of overseas business rose sharply. The first half of the year achieved net profit of 868 million yuan, an increase of 12.53% over the previous year; of these, net profit to mother was 426 million yuan in the second quarter of 2026, an increase of 27.63% over the previous year. The company's domestic business showed a recovery trend in the first half of the year, thanks to the company's major customer strategy in the domestic market that continued to advance in the domestic market for the past two years after experiencing price drops after the implementation of the domestic inter-provincial alliance procurement and the DRG/DIP policy, the company's domestic business showed a recovery trend in the first half of the year. The company continues its major customer marketing strategy and continues to expand large-scale domestic medical terminals through the promotion of high-speed chemiluminescence immunoanalyzers X10, X8, X6 and assembly line product T8. With the continuous deepening of the globalization strategy, the company's overseas business achieved a sharp rise in quantity and quality. Maintain a “buy” rating.